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BiocompatibilityPurpose: A successful gene therapy approach can prevent or treat congenital and acquired diseases. However,
there is still no ideal non-viral vector for genedelivery in a safe and timelymanner. In this report the anionic poly-
mer hyaluronic acid (HA) was investigated as a potential vector for gene therapy. Due to its intrinsic character-
istics it constitutes an excellent candidate to deliver therapeutic genes, pending the modiﬁcation of its surface
charge.
Methods: Tomodify its charge, HAwasmodiﬁedwith cystamine. Several formulationswere prepared usingmod-
iﬁed HA combined with sodium sulfate, sodium triphosphate, K-carrageenan and chitosan. Vectors were charac-
terizedwith respect to size, charge, DNA load and its protection, and effect on cell viability. The better performing
formulations were further evaluated in vitro for their transfection efﬁciency in HEK293T and ARPE-19 cells.
Results: Cell viability assays showed low cytotoxicity for both polymers. Gene transfer efﬁciency depended on cell
line and formulation, but no increased transfection efﬁciency was observed with the modiﬁed polymer.
Conclusions:HA has great potential as a gene therapy vector, but further optimization, including incorporation of
a higher percentage of positive groups in HA, is needed before its use as a gene delivery vector.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Gene therapy is an area that has been growing rapidly and revolu-
tionizing theworld of research [1]. An essential requirement for the suc-
cess of this technique is an efﬁcientmethod for gene transfer, since DNA
molecules cannot enter cells efﬁciently because of their large size, hy-
drophilic nature and susceptibility to degradation mediated by nucle-
ases [2,3]. Considering the great diversity of diseases targeted by gene
therapy, it is implausible that a single gene delivery system (vector) is
suitable for all applications. However, the main requirements are com-
mon to all systems: vectors should transfer the genetic material to the
tissue of interest and induce the proper level of therapeutic gene ex-
pression with no side effects [4].
Currently, vectors used in gene therapy can bedivided into twomain
categories: viral and non-viral. Recombinant viruses such as retrovirus,
lentivirus, adenovirus, adeno-associated viruses, and herpes virusesic acid; EDAC, 1-ethyl-3-(3-
; HASSNH2, hyaluronic acid-co-
N-cysteaminyl-hyaluronamide;have been widely used for genetic material transfer [2]. Viruses have
as main advantage their high transfection efﬁciency, however, viral
vectors entail many intrinsic problems such as difﬁculties in production,
limitations concerning repeated administrations that can lead to acute
inﬂammatory responses, immune responses of the host to the virus
and induction ofmutagenesis by some viruses that integrate into the ge-
nome of host cells [2]. On the other hand, non-viral vectors have a
higher safety proﬁle due to their low toxicity and low immunogenicity.
Additionally, non-viral vectors have the ability to carry larger genes and
present lower production costs. Despite this appealing feature from the
safety standpoint, non-viral vectors have little clinical importance due
to low transfer and expression of transgene [2]. However, due to prob-
lems in clinical trials using viral vectors in the recent past, the interest
in non-viral technologies has been renewed, particularly in the release
properties of the non-viral vectors that resemble traditional drugs [4].
Non-viral vectors include synthetic or naturally occurring chemical
compounds, such as lipids and cationic polymers. These can form com-
plexes with the negatively charged DNA through electrostatic interac-
tions that allow the therapeutic transgene across the cell membrane
via endocytosis [2,3,5]. The complexes protect DNA from nuclease-
mediated degradation and facilitate cell entry as well as gene transfer-
ring into the nucleus [2].
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construction of polymers withmultiple functionality, and thus more ef-
ﬁcient in gene delivery, while maintaining the characteristics of bio-
compatibility, easy production and stable formulation [4]. One of the
key points for the construction of more efﬁcient vectors relates to vari-
ous biological barriers of cells that must be overcome to achieve higher
transfection rate. These barriers include the attachment of the polymer
to the cell surface, then entering the cell through the cell membrane,
displacement throughout the cytoplasm, escape endosomal degrada-
tion and ending with the passage of the nuclear envelope and nuclear
entry [3]. In order to overcome different barriers, functional groups
can be introduced into polymers, such as ligands to enhance cell entry
via receptor-mediated endocytosis, membrane peptides to allow
endosomal release and nuclear localization signals to increase nuclear
entry of the transgene [3].
In this paper, hyaluronic acid (HA) was evaluated as a possible reti-
nal gene therapy vector. HA is a biocompatible, non-toxic, non-
immunogenic, non-inﬂammatory anionic biopolymer that has been
widely used in various biomedical applications [6]. Multiple studies on
the biological function of HA have revealed that there is a strong rela-
tionship between the presence of HA and the migration and prolifera-
tion of cells as well as an involvement in wound healing, cell motility,
angiogenesis, and extracellular matrix formation. Another important
feature of HA for its use as a vector of therapeutic genes is the ability
to interact with various cell receptors [6]. The negatively charged car-
boxyl group of HA is responsible for the interaction withmembrane re-
ceptors allowing the connection with HA [7].
Despite its advantageous features, HA exists in the form of an aque-
ous gel, has a short lifetime and quickly degrades after administration.
In order to increase the lifetime of HA for long-term clinical applications,
several strategies have been developed, particularly modiﬁcations of
the polymer at the level of carboxyl and hydroxyl groups. These new
polymers, although they have different physico-chemical properties
compared to unmodiﬁed HA, they maintain essential biological proper-
ties that allow their use in non-viral therapies [6]. Among possible
chemical modiﬁcations to perform, the more relevant for gene therapy
is the inclusion of amine groups [6]. A higher amount of amine groups
may lead to greaterDNA loads and increase the efﬁciency of transfection
and transgene expression. In this study, HA was modiﬁed with cysta-
mine through a coupling reaction with the carboxyl groups of HA. This
modiﬁcation with cystamine not only adds amine groups to the poly-
mer but it also contains a disulﬁde bond that can be cleaved in the pres-
ence of intercellular glutathione, thereby promoting a more rapid
release of genetic material [8,9].
In this work we compare the transfection efﬁciency between modi-
ﬁed and unmodiﬁedHAusing two types of cells: human embryonic kid-
ney (HEK 293T) cells and retinal pigment epithelium cells (ARPE-19).
The former are a commonly used cell line in transfection studies,
while the latter are a model of retinal pigmented epithelial (RPE) cells,
our target in the retina, due to their important role in the support of
the retinal homeostasis and involvement in several retinal diseases [8].
2. Materials and methods
2.1. Materials
Chitosan (MWof 80 kDa)with a degree of de-acetylation of 83%was
purchased from Polysciences, Inc., USA. Hyaluronic acid, with MWs of
132 and 214was purchased from Lifecore Biomedical. All other reagents
were analytical grade and used without further puriﬁcation.
2.2. Plasmid constructs and cell lines
A plasmid expressing enhanced green ﬂuorescent protein driven by
the cytomegalovirus promoter (kindly provided by Jean Bennett, Uni-
versity of Pennsylvania, USA) was ampliﬁed in Top 10 bacteria andpuriﬁed using a Plasmid Maxi kit (Qiagen, California, USA) following
manufacturer guidelines. Plasmid DNA (DNA) was dissolved in TE buff-
er, and the concentration was evaluated using a NanoDrop 2000c spec-
trophotometer (Thermo Scientiﬁc, Waltham, MA) at 260 nm.
Two cell lineswere used for transfection and cytotoxicity evaluation:
HEK 293T cells (kindly provided by Guilherme Ferreira, University of Al-
garve, Portugal) and a human retinal pigment epithelial cell line (ARPE-
19, kindly provided by Francisco Ambrósio, University of Coimbra). All
cell culture reagents were purchased from Sigma-Aldrich® (St. Louis,
MO/USA).
2.3. Methods
2.3.1. Modiﬁcation of hyaluronic acid with cystamine (HASSNH2)
The modiﬁcation reaction was performed in an adaptation of what
was previously described elsewhere and depicted in Fig. 1 [10–12].
Brieﬂy, 500 mg of hyaluronic acid was dissolved in 100 ml of distilled
H2O, a one and a halfmolar excess (relative to the carboxylic acid groups
in HA) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC,
0.378 g, 1.974 mmol), and three molar excess of cystamine (0.889 g,
3.947 mmol) were added to the solution. The mixture was stirred at
room temperature for 72 h. The reaction mixture was dialyzed against
4 g/l NaCl (MW cut off 2000) for 6 h and then against distilled H2O for
24 h. The ﬁnal product – HASSNH2 – was lyophilized for 3 days and
stored at room temperature until use.
2.3.2. Determination of the thiolation extent
In order to determine the extent of themodiﬁcation, the thiol groups
were quantiﬁed by the Ellman's test. Firstly, 50mg of HASSNH2was dis-
solved in distilledH2O and treatedwith30molar excess of dithiothreitol
(DTT, 0.418 g, 2.712mmol) in order to expose the thiol groups. Themix-
ture was stirred under N2 atmosphere for 24 h, at room temperature.
The reaction mixture was dialyzed against 4 g/l NaCl (MW cut off
2000) for 6 h and then against distilled H2O for 24 h. The ﬁnal product
HASH was lyophilized for 2 days and stored at room temperature until
use. Secondly, for the Ellman's test, 3.8 mg of HASH was dissolved in
1ml of 0.1 M Tris buffer, pH 8.0. For eachmeasurement, a tube contain-
ing 100 μl of Ellman's reagent (10mMof 5,5′-dithio-bis-(2-nitrobenzoic
acid) in 0.1M Tris buffer), 1800 μl of 0.1M Tris buffer and 100 μl of sam-
ple was prepared, incubated at room temperature for 15 min and then
the absorbance at 412 nmwas measured [13].
2.3.3. Potentiometric titration of HASSNH2
In order to characterize the protonation behavior of the modiﬁed
polymer, a titration was performed [14]. Polymer solutions, HA and
HASSNH2,were preparedwith a concentration of total titratable carbox-
yl group concentration of 10 mM in a volume of 10 ml. The initial pH
was adjusted to 2–3 by adding 2.00 M HCl prior to the dropwise addi-
tion of the titrant 0.08MNaOH to the polymer solutions under constant
stirring. Potentiometric measurements weremade using a pHmeasure-
ment electrode (Orion 9157BN) connected to an Orion pHmeter (Ther-
mo Orion 4 Star pH-ISE Benchtop; ThermoFisher Scientiﬁc (Waltham,
MA USA).
2.3.4. Polyplex preparation
Polyplexes were prepared as previously described by our lab [8,15].
Vector formulations were prepared at various ratios by adding anionic
solutions to the HASSNH2 solution, as indicated in Diagram 1. Brieﬂy,
polymer solutions (1 mg/ml in MilliQ H2O, pH 5.5) and sodium sulfate
solutions were separately heated to 55 °C. Equal volumes of both solu-
tions were quickly mixed together, vortexed for 30 s, placed on ice
and stored at 4 °C. Alternatively, HA and other anionic species (TPP
and κ-carrageenan) were tested by combining them to the sodium sul-
fate solutions. Different weight ratios were tested keeping constant the
HASSNH2 amount (250 μg) and varying the HA amount. In order to use
Fig. 1. Schematic representation of modiﬁcation reaction and conditions.
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then mixed with the HASSNH2 solution, as described above.
Vectors were prepared based on mixtures with chitosan (CS), origi-
nating CSHA or CSHASSNH2 vectors. The CS:HA or CS:HASSNH2 weight
ratios 5:1 and 7:1 were chosen based on previous studies [15], keeping
constant the CS amount (250 μg). In order to use equal volumes of both
solutions, HA or HASSNH2 was diluted in 25 mM sodium sulfate and
then mixed with the CS solution, as described above.
To prepare polyplexes loaded with DNA at a NH3+:PO4− ratio of 15:1,
250 μg of CS and 26.5 μg of DNA, were used. DNA was mixed with the
sodium sulfate solution and this solution mixed with the CS solution,
as described above. The resulting polyplex formulations are described
in Diagram 2.2.3.5. Polyplex characterization
Size analysis was performed by dynamic light scattering (DLS) with
a detection angle of 173°, and zeta potential (ZP) measured by laser
Doppler velocimetry (Zetasizer Nano ZS, Malvern instruments, UK).
All measurements were performed in ddH2O at 25 °C. The polydispersi-
ty index (PdI) was calculated based on DLS measurements using the
Zetasizer Nano Series software version 7.11.
The complexation and integrity of the plasmids (DNA) in the
polyplexes were assessed by gel electrophoresis. Free DNA and
polyplexes were incubated with 1 unit of DNAse I (Sigma-Aldrich®,
USA) for 15 min at 37 °C. The reaction was stopped by the addition of
1 μl of a 50mMEDTA solution and heating at 70 °C for 10min. Complex-
ation and integrity of the DNAwere analyzed by agarose gel electropho-
resis in 1% (W/V) agarose in TAE buffer with GreenSafe Premium
(NZYTech, Portugal). Gels were subjected to a 90 mV voltage for 1 hDiagram 1. Tested vector formulations with different anionicand further visualized under UV light (AlphaImager®, Alpha Innotech,
USA).
Polyplex stability was also evaluated regarding physiological tem-
perature (37 °C) and pH (7.4). Brieﬂy, polyplexes were incubated in
equal volumes of either PBS or DMEM (with 10% FBS [fetal bovine
serum]) at 37 °C for 1 to 3 days. Polyplex stability, evaluated by DNA re-
tention, was performed as described in the previous section.
To evaluate the cleavage of disulﬁde bonds incorporated into the
modiﬁed polymer, polyplexes were incubated with glutathione and
DTT. These assays were performed as described previously [8,9]. Brieﬂy,
a 0.4 M glutathione reduced-form (Sigma) stock solution was prepared
in 0.1M potassium phosphate buffer (pH 7.5), with 2 mM EDTA, pH 7.5
(potassiumphosphate bufferwith EDTA fromhere on referred to as PB).
Polyplexes, prepared as previously described, were incubated for 24 h at
37 °C in PBS in the presence of 20 mM glutathione, 2 units/ml of gluta-
thione reductase (GlutR; Sigma), and 0.5 mM of nicotinamide adenine
dinucleotide phosphate (NADPH, Sigma). Polyplexes were incubated
for 6 h at 37 °C with different concentrations of DTT (10 and 100 mM)
in sodium acetate at 10 mM. Samples were then analyzed by agarose
gel electrophoresis as described in the previous section.
2.3.6. In vitro assays
Cells were cultured at 37 °C, under a 5% CO2 atmosphere. Different
culture media were used, according to each cell's speciﬁcations:
HEK293T in Dulbecco's Modiﬁed Eagle's Medium (DMEM) and ARPE-
19 in DMEMmixture with F-12 HAM; both supplemented with 10% of
fetal bovine serum, 1% penicillin/streptomycin and 1% glutamine.
An MTT assay was performed to evaluate the cytotoxicity of the
polymers. Cells were seeded at a density of 1.5 × 104 cells/well in 48-
well ﬂat bottom tissue culture plates and the assay was carried out asagents and different weight ratios, nd—not determined.
Diagram 2. Polyplex formulations with chitosan and hyaluronic acid. All polyplexes containing DNA were prepared at a N:P ratio of 15:1. Formulation names used in subsequent studies
are shown in bold.
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taining different amounts of polymer (from 0.01 up to 0.1 mg/ml) for
24 and 72 h. As positive and negative controls of cell viability, cells cul-
tured in standard cell culture conditions and cells incubatedwith a latex
extract in culture medium (1.5 cm2/ml) were used, respectively. Absor-
bance was measured using a microplate reader (Tecan Inﬁnite 2000,
USA), at 570 and 630 nm, for cell viability/formazan formation and
background, respectively. Cell viability was calculated as follows: Cell
viability (%) = (ODsample) / (ODcontrol) × 100, where ODcontrol
and ODsample are cells not challenged and challenged by polyplexes,
respectively. Each value was averaged from triplicates and each experi-
ment was carried out thrice.
For the transfection studies, cellswere seeded at 2 × 105 cells/well in
6-well tissue culture plates 24 h prior to the transfection. FuGENE® HD
(Promega, USA) was used as positive transfection control according to
the manufacturer's instructions. Polyplexes were added to cells at a
ratio of 1 μg of DNA per well and further incubated for 5 h in serum-
free media. Then, media was replaced by complete media and transfec-
tion efﬁciency was evaluated quantitatively 72 h post-transfection by
ﬂow cytometry by scoring GFP-positive cells (FACScalibur, BD Biosci-
ences, USA) using FL-1H, green channel. A total of 5 × 104 events were
counted for each sample. The percentage of positive events correspondsFig. 2. Potentiometric titration curves of HA and HASSNH2 in water. The initial polymer solution
total initial solution volumeof 10.0ml and thepHof the solutionwas adjusted to 2.00–3.00with
denotes the total volume of added NaOH in μl).to the gated eventsminus the non-transfected cells. Transfection results
were also evaluated qualitatively by ﬂuorescence microscopy (Axiovert
40 CFL, Zeiss).
2.3.7. Statistical analysis
Results presented aremean± standard deviation of at least three in-
dependent experiments. Statistical analysis was performed with
GraphPad Prism version 6.04 software. Data were subjected to analysis
of variance and multiple comparisons tests using a conﬁdence interval
of 95%.
3. Results
3.1. Characterization of the modiﬁed polymer: degree of modiﬁcation
The ﬁrst step in the characterization of the polymer was to deter-
mine the extent of modiﬁcation by quantiﬁcation of the added thiol
groups. After treatmentwith an excess of DTT itwas possible to quantify
the thiol groups present in the polymer through Ellman's test. The aver-
age percentage of thiol substitution to the total carboxylic acid groups of
HA was 9.88% ± 0.34.s were prepared to contain a ﬁxed amount of protonable amine groups (0.100mmol) in a
2.00NHCl. The solutionwas then titrated using 0.0800NNaOH (the x-axis label of the plot
Fig. 3. Size, polydispersity and zeta potential of polyplexes. Statistical differences and their signiﬁcance are indicated by the star (*) symbol, with ***P b 0.001, ****P b 0.0001, ns — not
signiﬁcant.
268 A.V. Oliveira et al. / Materials Science and Engineering C 58 (2016) 264–272The behavior of HASSNH2 as a function of pHwas then evaluated by
titration, where the carboxylic group (COO−) was considered to be the
protonatable group. Comparing the unmodiﬁed and modiﬁed titration
curves it is possible to observe differences in the equivalence points
present conﬁrming the success of the modiﬁcation reaction (Fig. 2).3.2. Physical characterization of HASSNH2 polyplexes
Several conditions were tested in order to produce vectors formula-
tions with adequate characteristics. Firstly, formulations based on
HASSNH2 and different concentrations of anionic agents were tested
(Na2SO4, TPP, HA and κ-carrageenan) but did not yield polyplexes
with the appropriate size (b 500 nm) or polydispersity (b0.5, data not
shown). Then, formulations with the cationic polymer chitosan and
the modiﬁed polymer or HA were examined, yielding positive results
as described in Fig. 3. Only formulations CSHASSNH25N and
CSHASSNH27N presented size and polydispersity above average. Re-
garding polyplexes prepared in water (CSHA5H, CSHA7H,
CSHASSNH25H and CSHASSNH27H) these presented much higher zeta
potential values with approximately a 2-fold increase in the surface
charge.
Next, polyplexes were evaluated regarding their DNA complexing
capacity and nuclease protection. Polyplexes were capable of efﬁcient
DNA complexion and protection against DNAse-induced degradation,
as veriﬁed by agarose gel retardation assays (Fig. 4). Also, polyplexes
remained stable and did not release DNA in detectable amounts, even
after incubation for several days at physiological conditions. However,
upon incubation in media with serum in some of the formulations it is
possible to observe some DNA release (Fig. 5) indicating a less stable
polyplex. Nevertheless it is noteworthy that the DNA released by the
polyplexes is still undamaged whereas the free DNA used as control is
clearly degraded indicating the polyplexes did protect the DNA.
In order to evaluate the effect of a reductive environment on
polyplexDNA release, polyplexeswere incubated in the presence of glu-
tathione and DTT and DNA release was subsequently analyzed by gelFig. 4.DNA complexation andDnase I protection in polyplexeswere analyzed by 1% agarose gel
for 15 min at 37 °C (+) for formulations A) in H2O and B) in Na2SO4.retardation assays. No detectable amount of DNA was released from
the polyplexes in either condition, as observed in Fig. 6.
3.3. In vitro studies: cytotoxicity and transfection
The cytotoxicity evaluationwas performed by anMTT assay to study
possible changes in the cytocompatibility of the modiﬁed polymer by
comparison with the unmodiﬁed HA. The results are presented in
Fig. 7, and show no differences both for tested concentrations and
polymers.
After verifying that there were no cytotoxicity associated with the
polymers, the polyplexes were evaluated regarding their transfection
efﬁciency in two cell lines, HEK293T and ARPE-19, the ﬁrst are a com-
monly used cell line in transfection studies, while the latter are a
model of retinal pigment epithelial (RPE) cells, our target in the retina.
In ARPE-19 cells no differences between different formulationswere
foundwhereas in HEK293T there was statistically lower transfection ef-
ﬁciency when HASSNH2 polyplexes were prepared in sodium sulfate
(Fig. 8). Nonetheless, polyplexes prepared in water, with both HA and
HASSNH2, had similar transfection results (Figs. 8 and 9).
4. Discussion
4.1. HA was successfully modiﬁed with cystamine
Hyaluronic acidwasmodiﬁed by reaction of the carboxylic groups of
HAwith the amine groups of cystamine dihydrochloride using EDAC ac-
tivation. Later, a portion of the modiﬁed polymer was treated using an
excess amount of the DTT to cleave the disulﬁde bonds. The resulting
product (HASH) was puriﬁed by dialysis and isolated after freeze-
drying. The average percentage of thiol substitution (approximately
10%) was determined by Ellman's test. This percentage of substitution
is in agreement with values in the literature since it is considered that
a partial modiﬁcation (10–20%) is desirable to achieve polyplexes
with well-deﬁned sizes [10].electrophoresis andDNA visualizedwith GreenSafe Premium after incubationwith Dnase I
Fig. 5.DNA complexation in polyplexes was analyzed by 1% agarose gel electrophoresis and DNA visualizedwith GreenSafe Premium after incubationwith PBS or DMEMwith 10% FBS for
A) 3 and B) 7 days at 37 °C.
Fig. 6. DNA retention by polyplexes in reductive conditions: A) 24 h incubation in the presence of glutathione and glutathione reductase and B) 6 h incubation in the presence of dithio-
threitol (DTT); polyplexes in lanes: 1—CSHA5N, 2—CSHA5H, 3—CSHA7N, 4—CSHA7H, 5—CSHASSNH25N, 6—CSHASSNH25H, 7—CSHASSNH27N, 8—CSHASSNH27H.
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Fig. 7. Cytotoxicity inHEK293 and ARPE-19 cell line, given as percentage of viable cells after 24 or 72 h incubationwith polymer at increasing concentrations (0.01, 0.05 and 0.1mg/ml per
well). Un-challenged cells and cells incubated with latex extracts were used as positive and negative controls of cellular viability.
270 A.V. Oliveira et al. / Materials Science and Engineering C 58 (2016) 264–272The presence of two equivalence points in the potentiometric titra-
tion curve of HASSNH2 further conﬁrmed the success of the modiﬁca-
tion reaction and indicated the pH range more adequate for polyplex
preparation. At pH values much below the ﬁrst equivalence point the
carboxyl groups are predominantly deprotonated. This may hinder the
preparation of polyplexes because in this case carboxyl groups may in-
teractwith amine groups in the polymer, leaving very few amine groups
available to interact with DNA phosphate groups. On the other hand, at
pH values exceeding the second equivalence point all amine groups are
deprotonated and there are fewer positive charges available to interact
with DNA phosphate groups, establishing less electrostatic interactions.
Thus it is preferable to prepare polyplexes at pHvalues between 6 and9,
which is also desirable for later in vitro and in vivo experiments.
4.2. HASSNH2 does not produce polyplexes with anionic agents
Initially nanoparticles were evaluated and characterized with re-
spect to their size and polydispersion. Several formulations with
HASSNH2 and different concentrations of anionic agents were testedFig. 8. Transfection efﬁciency 72 h post-transfection in HEK293T and ARPE-19 cells as percentag
(*) symbol, with *P b 0.05, ****P b 0.001, ns— not signiﬁcant.(Na2SO4, TPP, HA and κ-carrageenan) with no satisfactory results.
HASSNH2/DNA polyplexes were also tested at various N:P ratios but
complete complexation was not achieved (data not shown). The modi-
ﬁed polymer was unable to generate polyplexes by itself or with the ad-
dition of other anionic agents, probably due to insufﬁcient electrostatic
interactions. This may be related to the degree of substitution of the
modiﬁed polymer that seems to have a low number of positive charges
available to interact. In order to increase the number of positive charges
and foster electrostatic interactions, chitosanwas added to the formula-
tion yielding the results described in the next section.
4.3. CSHA and CSHASSNH2 polyplexes: a comparison
Previous studies in our lab had shown positive results in terms of
transfection with formulations based on chitosan and hyaluronic acid
[15]. In this studywewanted to evaluate and compare the performance
of polyplexes prepared with normal unmodiﬁed hyaluronic acid and
polyplexes prepared with HASSNH2. Different formulations were pre-
pared and the ﬁrst step in their evaluation was to characterize theme of GFP positive cells. Statistical differences and their signiﬁcance are indicated by the star
Fig. 9. Fluorescence images of transfected cells 72 h post-transfection. Non-transfected cells and cells transfectedwith FuGENEHDwere used as negative control (C−) and positive control
(C+), respectively. Cells transfected with different formulations: A) CSHA5H, B) CSHA5N, C) CSHASSNH25H, D) CSHASSNH25N, E) CSHA7H, F) CSHA7N, G) CSHASSNH25H,
H) CSHASSNH25N. Total ampliﬁcation 100×.
271A.V. Oliveira et al. / Materials Science and Engineering C 58 (2016) 264–272for their size, polydispersity, and zeta potential (Fig. 3). Polyplexes were
compared through a statistical multiple comparison analysis. Among
the various comparisons, those with higher signiﬁcance for the inter-
pretation of the results were comparisons 1) between formulations
with different solvents but the same polymer and ratio; 2) between for-
mulations with different ratios while maintaining the same polymer;
and 3) between formulations with different polymers but keeping the
same ratio and solvent. Given the comparisons described above, in
Fig. 3 are represented all comparisonswith a signiﬁcant statistical differ-
ence. All other comparisons show no statistical difference.
The different formulations yielded polyplexes with similar sizes ex-
cept for CSHASSNH25N and CSHASSNH27N. These two formulations
also presented high polydispersity and a slightly lower surface charge
(given by the zeta potential values). The zeta potential can be used to
predict the stability of the dispersion so this reduced surface charge
might have caused aggregation of the polyplexes hence the large size
and polydispersity [16]. Since chitosan is a polycation, a positive zeta
potential was expected, which occurred in all cases. However, statistical
differences were observed between polyplexes with the same polymer
and ratio but different solvents (Na2SO4 and H2O). This may be due to
the presence of the negative charges from sulfate anions, which reduce
the overall surface charge.
4.4. Polymer modiﬁcation did not affect cytotoxicity
The cell viability assay main objective was to evaluate the possible
cytotoxic effect of the polymers in the cells after DNA release and to as-
sess if the modiﬁcation changed the polymer cytotoxicity proﬁle. HA is
known as a biocompatible polymer and studies have shown that it is
safe for concentrations up to 1–2% (W/V) [17,18]. Comparing the results
obtained for the HA and HASSNH2 polymers, no statistical differences
were observed in all four tested situations. This is possibly due to thefact that the difference in composition of the two polymers is small,
since only 10% modiﬁcation was achieved, and this did not sufﬁciently
alter the toxicity proﬁle of the polymer.
However, after 24 h of incubationHA andHASSNH2 showed a reduc-
tion of cell viability in HEK293 cells for all tested concentrations when
compared to the control. Thiswas not observed for the other tested con-
ditions and this could be related to the fact that at 24 h the cells
underwent acute exposure while at 72 h it resembles a chronic expo-
sure. The fact that the cell viability had decreased slightly in some
cases may also be related to the fact that the polymer solutions have
not been extensively puriﬁed before addition to cells, and so the ob-
served cytotoxicity may be due to residual impurities of the modiﬁed
polymer. Nevertheless, at concentrations to be used in future in vitro
and in vivo transfection studies, no cytotoxicity was observed.4.5. Polyplex stability at physiological conditions varies with temperature
and presence of serum
All polyplexeswere capable of efﬁcientDNA complexion and protec-
tion against DNAse-induced degradation when exposed to DNase I (Fig.
4). This is a critical aspect for all non-viral vectors, since a successful
gene therapy vector needs to protect its load until it reaches the target
and only unload it at the appropriate time [19,20]. Our stability assay re-
sults shown that all polyplexes remained stable up to 7 days at physio-
logical temperature and pH (polyplexes incubated with PBS). However,
when polyplexes were incubated in DMEM with serum some DNA re-
lease was observed, particularly in polyplexes with the modiﬁed poly-
mer. It is hypothesized that serum components establish electrostatic
interactions with the polyplexes, destabilizing them, and causing DNA
release. The fact that polyplexes prepared with the modiﬁed polymer
appear less stable can actually be advantageous since several studies
272 A.V. Oliveira et al. / Materials Science and Engineering C 58 (2016) 264–272have shown anegative correlation between polyplex stability and trans-
fection efﬁciency [15,21–23].
4.6. Transfection efﬁciency is formulation-dependent
One of the main objectives of this study was to evaluate if the mod-
iﬁcation of HA would affect the stability of the polyplexes and conse-
quently their transfection efﬁcacy. In our study, different formulations
of CSHASSNH2 polyplexes showed very similar transfection efﬁciencies.
Analyzing the results obtained for ARPE-19 and HEK293 cells, the latter
had much higher transfection efﬁciency in all formulations due to their
higher permissibility to transfection, associatedwith their highermitot-
ic rate. Despite the higher transfection values there were only differ-
ences in the transfection efﬁciency between CSHA and CSHASSNH2
polyplexes prepared in sodium sulfate. These polyplexes
(CSHASSNH25N and CSHASSNH27N) were expected to have a reduced
efﬁcacy since their size was too large for an efﬁcient and timely cellular
internalization and this was indeed conﬁrmed.
Moreover, less stable formulations, with visible DNA release in the
stability assay, displayed higher transfection values as expected, based
on the aforementioned relation betweenpolyplex stability and transfec-
tion efﬁciency.
Polyplex charge is a key parameter due to its association with toxic-
ity and transfection efﬁciency. Other studies have shown an association
between surface charge and increased transfection efﬁciency as well as
a decrease in toxicity [24,25]. Also, cellular uptake is one of the major
obstacles for a successful gene delivery strategy and polyplexes are
thought to enter the cell via endocytosis in a process thatmay be depen-
dent on polyplex charge [26]. A higher surface charge can facilitate elec-
trostatic interactions with the negatively charged proteoglycans in
cellular membranes and hence promote polyplex internalization [27].
Our results show a positive correlation between polyplex surface charge
and transfection efﬁciency that is in agreement with the literature.
Polyplexes prepared in water displayed nearly a 2-fold increase in sur-
face charge that correlated with higher transfection values, irrespective
of the polymer used. This data strongly indicates that the preparation
method used for polyplex formation is as important as the polymer
used.
5. Conclusions
Thiswork had asmain objective the characterization of a novel poly-
mer, HASSNH2, for subsequent use as a retinal gene therapy vector.
After conﬁrming the success of themodiﬁcation reaction and determin-
ing its extent (~10%), several strategies were tested in order to yield
polyplexes with adequate characteristics. The resulting polyplexes
were capable of effective DNA complexation though their stability at
physiological conditions varied. Transfection studies using HEK293
and ARPE-19 cells showed relatively modest transfection efﬁciency
where no differenceswere observed between polyplexeswithmodiﬁed
or unmodiﬁed HA. Higher transfection values correlated with lower
polyplex stability as well as higher surface charge.
In the future, higher degrees of modiﬁcation will be pursued by in-
troducing changes in the reaction conditions, in order to modulate the
stability andDNA release from the polyplexes, to allow further improve-
ment of the transfection efﬁciency of these gene therapy vectors.
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